• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)?

    Simply Wall St·08/14/2026 13:32:03
    Listen to the news
    • Nektar Therapeutics has reported past second-quarter 2026 results showing revenue of US$10.13 million and a net loss of US$40.62 million, while also launching global Phase III trials of rezpegaldesleukin in atopic dermatitis and planning Phase III development in alopecia areata, supported by US$1.02 billion in cash and investments with no debt.
    • An interesting angle for investors is that Nektar’s smaller‑than‑expected quarterly loss, extended cash runway into the third quarter of 2028, and Fast Track‑backed Phase III program for rezpegaldesleukin collectively strengthen its ability to pursue late‑stage development without immediate financing pressure.
    • We’ll now examine how the Phase III rezpegaldesleukin launch and extended cash runway shape Nektar Therapeutics’ existing investment narrative.

    Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

    Nektar Therapeutics Investment Narrative Recap

    To own Nektar Therapeutics, you need to believe that rezpegaldesleukin can clear late stage trials and eventually underpin a viable immunology franchise, despite ongoing losses and heavy R&D spend. The latest quarter’s smaller loss, extended cash runway into Q3 2028, and Phase III launch help reduce near term financing risk, but do not change the core binary risk around rezpegaldesleukin’s Phase III outcomes, which remains the key catalyst and the biggest fundamental risk.

    The most relevant recent update here is the initiation of the global Phase III ZENITH AD program for rezpegaldesleukin in moderate to severe atopic dermatitis, with top line data targeted for mid 2028. This step formally shifts Nektar into late stage development for its lead asset and aligns the extended cash runway with the expected readout window, so near term attention is likely to stay firmly on trial execution, regulatory interactions, and any interim clinical or safety updates.

    Yet investors should also be aware that if rezpegaldesleukin’s Phase III data fall short or timelines slip materially, the company’s dependence on a single late stage asset could...

    Read the full narrative on Nektar Therapeutics (it's free!)

    Nektar Therapeutics' narrative projects $54.9 million revenue and $10.7 million earnings by 2029. This assumes revenue remains flat each year and a roughly $168.8 million earnings increase from -$158.1 million today.

    Uncover how Nektar Therapeutics' forecasts yield a $153.25 fair value, a 102% upside to its current price.

    Exploring Other Perspectives

    NKTR 1-Year Stock Price Chart
    NKTR 1-Year Stock Price Chart

    Some of the most optimistic analysts were already assuming revenue could reach about US$136.0 million by 2029 with positive earnings, which is a far more aggressive outcome than the baseline view that Nektar stays unprofitable, so you should expect those projections and the tighter cash burn risk to be revisited as the new Phase III and funding details are fully absorbed.

    Explore 3 other fair value estimates on Nektar Therapeutics - why the stock might be worth just $153.22!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Want Some Alternatives?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.